Abstract: Nanoparticle drug formulations have enormous application prospects owing to achievement of targeted and sustained release drug delivery, improvement in drug solubility and reduction of adverse drug reactions. Recently, a variety of efficient drug nanometer carriers have been developed, among which carbon nanotubes (CNT) have been increasingly utilized in the field of cancer therapy. However, these nanotubes exert various toxic effects on the body due to their unique physical and chemical properties. CNT-induced toxicity is related to surface modification, degree of aggregation in vivo, and nanoparticle concentration. This review has focused on the potential toxic effects of CNTs utilized as anti-tumor drug carriers. The main modes by which CNTs enter target sites, the toxicity expressive types and the factors affecting toxicity are discussed.
Introduction
Malignant tumors are one of the leading causes of human disease and death, contributing to increasing mortality rates over the years. 1 All clinically available anti-cancer drugs have several limitations, such as poor stability, low bioavailability, 2 restricted targeting ability, degradation and potential drug resistance. [3] [4] [5] Although breakthroughs have been achieved in the clinical field of oncology, various treatment options have been shown to cause damage to normal cells along with eliminating tumor cells, resulting in local or systemic toxicity. Therefore, development of a targeting drug system (TDS) that allows delivery of drugs to tumors while avoiding injury to normal tissue is essential to improve therapeutic efficacy. Nanometer TDS based on the advantages of nanotechnology has developed rapidly in recent years. Nanometertargeted preparations have successfully achieved improved drug solubility and bioavailability and specific targeting of drugs to organs or cells, allowing sustained or controlled release, prolongation of drug retention times, and more rapid and efficient drug entry through physiological barriers. These preparations have enriched the selection range of pharmaceutical dosage forms and thus attracted considerable research attention. Nanometer materials are ubiquitous in biomedical fields, including in vivo imaging, 6 cancer treatment, 7 targeted transport 8, 9 and drug discovery. 10 CNTs are a type of highly efficient nanometer TDS displaying adequate adsorption activity that have considerable potential as anticancer drugs with high selectivity for tumor sites. 11, 12 Recent in vitro studies have shown that CNTs internalize into mammalian cells easily, effectively transporting molecular cargo into the cytoplasm and potentially nucleus. [13] [14] [15] [16] CNTs mainly comprise multiple coaxial tubes composed of hexagonal carbon atoms. A seamless, hollow tubular novel nanometer material is rolled into a graphite sheet constituting carbon atom bonds (sp 2 hybridization). 17, 18 According to the number of sp 2 hybrid carbon atoms, CNTs are subdivided into single-walled carbon nanotubes (SWCNT) and multi-walled carbon nanotubes (MWCNT). Due to their unique structures, SWCNTs and MWCNTs display excellent physical, chemical, electrical and thermodynamic properties, such as ultra-high specific surface area, good adsorption ability, unique fluorescence, and Raman spectroscopy in the nearinfrared region. 19, 20 CNTs can convert infrared light to heat and effectively utilize the property of poor heat resistance of tumor cells. At a tumor site temperature of >42°C, cell killing phenomena are evident, such as destruction of cell membrane, denaturation of proteins and irreversible damage of tumor cells, 21, 22 while normal cells remain intact. These anti-tumor effects are greatly enhanced upon coupling with anti-tumor drugs. 23, 24 Combination of CNTs with inorganic materials, polymers, can be utilized as a strategy to simultaneously diagnose and treat cancers. [25] [26] [27] As a nanometer carrier type displaying high drug loading, strong targeting and easily penetrable cell membranes, 28, 29 CNTs are commonly employed in multiple biomedical fields, in particular, drug delivery [30] [31] [32] [33] and cancer treatment. [34] [35] [36] On the other hand, the safety of clinical application of CNTs as anti-tumor drug carriers has been a subject of concern in recent years. 37 Toxic effects exerted by CNTs mainly stems from their similarities in structure to asbestos fibers. [38] [39] [40] 48, 49 Induction of toxicity by anti-tumor nanometer preparations of carrier CNTs may be attributable to the specific methods used for the experiment and related to surface modification, degree of aggregation, and nanotube concentration.
In an earlier study, Jabr-Milane and co-workers bound doxorubicin (DOX) to the SWCNT complex for targeting WiDr colon cancer cells. Upon separation of the DOX-SWCNT complex, DOX was released into the nucleus while SWCNTs remained in the cytoplasm. 50 Following injection of SWCNT into tumor-bearing mice, transmission electron microscopy (TEM) observation disclosed a large quantity of SWNT in urine of mice after 30 min. After 2 h, SWCNTs were collected from blood-rich tissues, such as liver and heart, and showed accumulation in the tumor area after 20 h. 51 Free CNTs were preferentially distributed in normal tissues, giving rise to the concern that these nanomolecules may be more toxic to normal than tumor cells. 52 This review has focused on the toxicity of CNTs used as anti-tumor carriers in terms of: (1) main routes used by CNTs to enter the target site; (2) toxicity expressive types; and (3) the factors affecting toxicity.
Entry Mechanisms of Anti-Tumor Carriers CNTs into Target Sites
Relative to the low cell permeability of macromolecules and small-molecule anticancer drugs, CNTs are considered a highly efficient novel material carrier for the delivery of anticancer drugs and diagnostic molecules. 53, 54 CNTs containing antitumor drugs should be delivered to cancer cells from the site of administration. Subsequently, free CNTs are dispersed from the target site to the excretory organ. 55, 56 The ability of CNTs to move forward in vivo may depend on their chemical reactivity, surface characteristics, and ability to combine with body proteins. 57, 58 CNTs transport anti-tumor drugs into target cells through two principal pathways: non-energydependent diffusion and energy-dependent endocytic pathways 59, 60 ( Figure 1 ). The differences in access routes are related to CNT size. 61 Kan and colleagues co-cultured SWNTs of different lengths with Hep G2 cells for 5 h. Confocal imaging and flow cytometry data disclosed that the internalization of L-SWNTs into cells mainly occurred through energy-dependent endocytosis. S-SWNTs partly utilized energy-independent pathways such as diffusion across the cell membranes for cell entry. 62 The group of Imaninezhad further highlighted that integrins promote CNT entry into cells.
In their experiments, CNTs were co-cultured with NIH 3T3 fibroblasts and PC12 neuron-like cells and randomly divided into two groups (one treated with an integrin inhibitor CWHM-96). Cells treated with CWHM-96 spread further and showed elongated shape while control cells with no CWHM-96 displayed round morphology. These findings confirmed that integrins promote CNT entry into cells, leading to more significant effects.
Non-Energy-Dependent Diffusion Pathways
The length and chemical nature of CNTs are the main factors affecting entry into target cells. 63 Since the cell membrane consists of a phospholipid bilayer, CNTs in the non-energy diffusion pathway enter the cell based on their diminutive sizes (submicron-sized) and hydrophobicity. Pantarotto and co-workers 64 incubated HeLa cells with CNTs containing sodium azide (an inhibitor of energy-dependent cellular Oxidative stress is one of the leading causes of cytotoxicity. 88, 89 During the process of CNT entry into cells for degradation, high levels of ROS are induced, leading to destruction of cellular structure and enhanced lethality against cancer cells. Homeostasis may be disrupted upon significant elevation of intracellular ROS levels. However, during the process of blood transport, CNTs are also in contact with normal cells. Excessive ROS levels can trigger DNA strand breakage, 90 protein-peptide chain disruption, 91 lipid peroxidation 92 and other macromolecular damage, eventually leading to cell death. 93, 94 The main targets of CNT cytotoxicity are cell membrane, lysosome, mitochondria, nucleus and cytoskeleton (such as actin). Damage to these structures induces loss of phagocytic ability, release of ROS, and injury to normal tissues. 95, 96 At the molecular level, many of the mechanisms underlying CNT toxicity involve specific cellular signaling pathways and programs. Signaling pathways activated by CNTs include NF-kB, NLRP3 inflammasome, p53, TGF-β, and MAPK. 93 However, these pathways may be involved in the development of fibrosis, leading to cytotoxicity and apoptosis of normal cells. Huaux et al 97 proposed immunosuppression as another mechanism of CNT-induced cytotoxicity. In their experiments, a specific type of CNT, Mitsui-7 CNT, was injected into the peritoneal cavity of Wistar rats and C57BL/6 mice for 12 months, and development of mesothelioma and monocytic myeloid-derived suppressor cells (M-Changes in MDSC) were examined. In the early stages of CNT-induced mesothelioma formation, M-MDSC rapidly and continuously accumulated in the peritoneal cavity of rats, preventing tumor cell monitoring by immune cells and thereby inducing mesothelioma. The group of Shvedova additionally reported that CNT-induced lung tumor formation is associated with the upregulation of MDSC. 98 Therefore, immunosuppression presents another key mechanism underlying cytotoxicity, mainly through accumulation of MDSC and upregulation of TGF-β toxicity, promoting tumor emergence. 99 Toxic Manifestations of Anti-Tumor Drug Carrier CNTs Figure 2 This figure shows the sites that CNTs may accumulate after separation from anticancer drugs, resulting in toxicity to different organs. CNTs mainly cause damage and toxicity to organs such as heart, liver, lung, kidney, brain and embryo. 
Pulmonary Toxicity
The lung is the target organ of nanoparticles and one of the pathways of nanoparticle entry into the body. Some nanoparticles are engulfed by pulmonary macrophages or absorbed by epithelial cells and finally deposited in the lungs. 114, 115 A proportion of nanoparticles can also be transferred to liver, embryo, kidney and lymph nodes, causing toxic effects in other organs. 116 Nanoparticles induce significant production of ROS, which have an oxidative stress effect. Pulmonary toxicity of CNTs is mainly attributable to their similar structures to asbestos. Inhalation of asbestos fibers is known to trigger asbestosis, lung cancer and pleural malignant mesothelioma. 40 Epithelioid granulomas and small nodules have been reported in the lungs of rodents as a dosedependent inflammation. Even purified CNTs are known to induce granuloma in the lung. 114, [117] [118] [119] At the same time, even purified CNTs are known to induce granuloma in the lung. 41, 120 Anti-tumor nanoparticles used as therapy for lung cancer reach the organ and effectively act on cancer cells but can additionally exert toxic effects on normal cells. The group of Chou divided ICR mice into two groups (untreated control and treatment group administered a single dose of 0.5 mg/kg SWCNTs into the trachea). On day 3, the condition of mice was assessed. Foamy macrophages with SWCNTs in the injection group had accumulated in the alveolus. After day 14, granuloma containing multifocal macrophages was produced around the SWCNT aggregation site and chronic lung inflammation observed. In these in vivo experiments, production of granulomas promoted SWCNT cytotoxicity characterized by abnormal lung inflammation. 121 In a study by Ming et al, 122 0, 0.1 and 0.5 mg CNTs were instilled into trachea of mice (using carbon black as a negative control). Animals were euthanized 7 and 90 days after a single treatment and the lungs isolated for histopathological analysis. In terms of changes, CNT aggregation in alveolar macrophages and concentrationdependent cytotoxicity were observed. Inflammation around bronchi was evident 7 days after treatment, with a more pronounced degree of inflammation at 90 days after administration. In contrast, the lungs of mice remained unaffected in the control group. These experiments clearly demonstrated serious damage induced by CNTs to lung. In another study, Qin and co-workers injected SWCNT into the tail vein of experimental mice, which were assigned to six groups (1, 7, 30, 60, 90 and 120 days). At the end of each time-period, 8 mice were randomly selected and lungs removed for follow-up studies.
The results showed that the total amount of carbon in lung was positively correlated with length of time. Pulmonary capillary continuous embolization, granuloma formation, pulmonary fibrosis, and numerous pro-inflammatory factors were stimulated. 123 Therefore, consideration of the chronic toxicity and cumulative toxicity of free CNTs distributed in the body is essential before clinical application of CNTs as anti-tumor drug carriers.
Cardiovascular Toxicity
CNTs released in the body are strongly dependent on the blood vessel wall. These nanomolecules have a significant killing effect on tumor blood vessels and can also cause cardiovascular damage during circulation in the body. CNTs possess high hardness and mechanical strength, which may cause mechanical damage upon contact with the vessel wall. 124 Furthermore, CNTs can trigger substantial release of ROS or inflammatory factors, leading to cellular damage and inhibition of growth. At the same time, these nanotubes could affect the reconstruction of new blood vessel walls and cause myocardial ischemia, leading to cardiovascular toxicity, such as atherosclerosis. 125 Ge et al 126 administered a solution containing SWCNTs to male spontaneous hypertensive rats once a day for two continuous days, followed by examination of mouse hearts. Compared with the control group, arterial vascular thickening and myocardial fibrosis were evident in treated mice. Capillary congestion and spongy appearance were obvious upon microstructural analysis, along with thrombosis and oozing of blood vessels as well as mitochondrial swelling.
The results clearly suggest that that SWCNTs cause damage to the cardiovascular system and are therefore a high risk for patients with cardiovascular disease. Similar findings were reported by Chen et al 127 who highlighted the risk of long-term toxicity of SWCNTs. The effects of CNTs on important monocyte adhesion during atherogenesis and endothelial progenitor cells (EPCs) isolated from human atherosclerotic model ApoE/mouse bone marrow were ascertained by Suzuki and co-workers. 128 To this end, normal human aortic endothelial cells (HAECs) were cultured and exposed to SWCNTs for 16 h. ApoE/mice were exposed to SWCNTs or DWCNTs (10 or 40 μg/mouse) once every other week for 10 weeks via pharyngeal aspiration. As a result, adhesion molecule (ICAM-1) was upregulated and THP-1 monocyte adhesion with HAEC enhanced. Compared with the blank group, the ApoE/mouse plaque area was increased, as observed from aortic oil red O staining, and ICAM-1 expression upregulated. The study concluded that SWCNTs and DWCNTs enhance atherogenesis by promoting adhesion of monocytes to endothelial cells and inducing EPC dysfunction. Cell morphology of human umbilical vein endothelial cells (HUVEC) co-cultured with MWCNTs (0.5, 5 and 20 μg/ mL) for 24 h was examined by the group of Guo. Microscopic examination revealed formation of cell solute vacuoles, disordering of cellular orientation and decreased cell densities. TEM analysis showed that compared with the control group, the MWCNT group (20 μg/mL, 24 h) displayed significant vacuolization and internalization of HUVECs, with vacuoles containing several MWCNTs. Moreover, MWCNT-induced cytotoxic effects were dosedependent. Flow cytometry using Annexin V-FITC and PI staining was used to examine the extent of HUVEC apoptosis in the MWCNT-treated groups. Cells in the MWCNT group showed a greater decrease in viability relative to control cells, indicating that the decrease in HUVEC activity may be at least partially attributed to MWCNT-induced apoptosis.
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Other Toxicities
Upon administration of CNT anti-tumor drug carriers, free CNTs not only accumulate in normal cell but are also distributed through the blood to other organs and exert toxic effects. The studies below represent recent investigations on the toxicity of CNTs to various tissues and organs (Table 1) .
Factors Influencing CNT-Induced Toxicity
Unlike traditional chemical materials, surface modification, aggregation, concentration, size and shape of CNTs are associated with biological effects. To optimize the therapeutic efficacy of CNTs in the medical field, elucidation of the factors and mechanisms underlying CNTmediated toxicity is critical.
Surface Modification
Surface modification is performed to improve the dispersion, excretion, and biocompatibility of CNTs. 145, 146 Poor water solubility of CNTs carrying anti-tumor drugs is a major contributory factor to their toxic effects on the body, which may be addressed by surface modification. [147] [148] [149] [150] The addition of proteins and surfactants on the CNT surface has been shown to not only facilitate effective targeting of cancer cells but also reduce toxicity 83 and improve therapeutic effects. [151] [152] [153] [154] Among these, folate receptors are expressed on a variety of tumor cells, and binding of folate to CNTs improves both tumor targeting and toxicity in vivo. [155] [156] [157] Ji and co-workers 158 designed a novel drug delivery system involving modification of chitosan (CHI) on the surface of SWNTs to control the loading and release of the anticancer agent DOX, which led to simultaneous improvement of the water solubility and biocompatibility of SWNTs.
Loading of folic acid (FA) on SWCNTs was shown to achieve targeted killing of tumor cells. In these experiments, the liver cancer cell line, HCC SMMC-7721, was treated with DOX and DOX/FA/CHI/SWNT (100 μg/mL), and cell viability recorded at 24, 48 and 72 h. The results showed lower cell viability of the DOX/FA/CHI/SWNT than the DOX group, indicative of time-dependent inhibition of liver cancer growth in nude mice. Wu et al 159 performed surface functionalization of CNTs via enrichment of carboxylic groups with optimized oxidization treatment, followed by covalent linking of hydrophilic diaminotriethylene glycol via amidation reaction. Finally, hydroxylcamptothecin (HCPT) was chemically attached to CNTs through a cleavable ester linkage to successfully generate a novel MWCNT drug delivery system. Subcutaneous liver H22 tumor-bearing mice were used as model animals for injection of MWCNT-HCPT (5 mg/kg). After 15 days, compared with the currently used HCPT preparations, tumors treated with the MWCNT-HCPT complex were extensively damaged while normal tissue sites remained relatively unaffected. Overall, the newly generated MWCNT-HCPT complex showed excellent antitumor activity and low toxicity. Furthermore, the complexity of MWCNT-HCPT led to longer blood circulation times and higher tumor-specific drug accumulation. Therefore, reasonable surface modification of CNTs should enhance the antitumor effect and decrease toxicity to normal tissues of the body. The group of Patlolla additionally evaluated the toxicity of primary and oxidized MWNTs on normal human dermal fibroblasts (NHDF). To this end, NHDFs were cultured with three different concentrations (40, 200 , 400 g/mL) of raw and oxidized MWCNTs. The results showed dosedependent toxicity of both MWNT types. Compared to the control group, 400 g/mL oxidized MWNTs inactivated NHDF via DNA damage. 111 Therefore, for effective utilization of CNTs as drug carriers, both the concentrations of CNTs accumulating in the body and modifying groups on the CNT surface need to be considered.
Degree of Aggregation
Nanoparticles with small particle size and large specific surface area have intense aggregation tendency owing to van der Waals attractions in solution. 160 A number of studies have indicated that SWCNT toxicity in vivo is caused by aggregates rather than individual molecules. 161, 162 Highly aggregated CNTs can become bulky and strong, 163 consequently exerting more harmful effect on cells.
To investigate the potential lung toxicity of dispersed SWCNTs, Mutlu et al 107 administered equivalent doses of dispersed and aggregated SWCNTs for 30 days after intratracheal administration to mice. Dispersed SWCNTs were taken up by alveolar macrophages through cilia via mucosal clearance or other mechanisms that gradually cleared over time. Aggregated SWCNTs displayed a granulomatous structure with mild fibrosis in mouse trachea. Accordingly, it was concluded that the toxicity caused by SWCNTs in vivo is mainly attributable to aggregates rather than SWCNTs with a large aspect ratio. 164 A number of studies have highlighted that dispersed MWCNTs with extreme aspect ratios induce higher cytotoxicity than those with low aspect ratios. 165 In a study by Wick et al 166 the mesothelioma cell line, MSTO-211H, was exposed to disperse CNT bundles and three different concentrations of CNT agglomerates (7.5, 15 and 30 g/mL). After three days, significant cellular morphological changes and decreased cell activity were observed in the CNT aggregation groups. Toxicity was increased in a concentration-dependent manner. CNTs exert toxic effects on cancer cells, and therefore, damage to normal cells is not unexpected. Belyanskaya and co-workers studied the effects of SWCNTs with varying degrees of aggregation on chicken embryonic spinal cord and dorsal root ganglia. Two dissimilar degrees of agglomerates were utilized, specifically, SWCNT agglomerates (SWCNT-a) and better dispersed SWCNT bundles (SWCNT-b). The overall DNA content of mixed glial cells in SWCNT-a and SWCNT-b groups at a concentration of 30 μg/mL was determined with the Hoechst assay, which revealed a marked decrease in the DNA content in the SWCNT-a group. SWCNTs induced acute toxicity in the central and peripheral nervous systems after entry into the body. 167 Moreover, the level of toxicity was dependent, in part, on the agglomeration state of SWCNTs. Dispersed SWCNTs showed an increased aspect ratio relative to the resulting aggregates. Phagocytic cells were able to eliminate SWCNTs and reduce toxicity to the body to a greater extent.
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Concentration
After anti-tumor nanometer preparations with CNTs are separated from target organs and drugs, a proportion is removed from the body while the remainder translocates to different parts of the body via the blood circulation and exerts toxic effects. The magnitude of toxicity is significantly correlated with the concentration of aggregated CNTs. 170 Bottini et al 137 incubated T lymphocyte cells with 40 μg/mL and 400 μg/mL CNTs and collected them for examination at different time-periods. The trypan blue exclusion assay was employed to assess the effects of CNTs on T cell viability and annexinV binding assay used to determine cell apoptosis. Cells lost 80% viability within 5 days in the presence of 400 μg/mL CNTs. Further microscopic examination was performed for chromatin condensation and membrane vesicles, which are markers of apoptosis. At a concentration of 40 μg/mL, CNTs did not appear to have toxic effects on T cells, leading to the conclusion that CNTs do not cause measurable damage to cells at this concentration and toxicity is positively correlated with dose. Fanizza and co-workers evaluated MWCNT toxicity to human bronchial normal cells (BEAS-2B) by exposing cells to 10, 40 and 100 μg/mL MWCNTs. Cellular microvilli structural changes, microvilli reduction and mild herpes development were observed after 24 h. At the same time, cell DNA damage in the 40 and 100 μg/mL MWCNT-treated groups was evident after 4 h using the comet assay. Data from these experiments confirmed the cytotoxicity of MWCNTs in normal cells. 171 In an earlier investigation, El-Gazzar and co-workers divided rats into DWCNT and MWCNT-7 treatment groups. Equivalent doses of DWCNT and MWCNT-7 were administered via intratracheal intrapulmonary spray every other day for 15 days and rats sacrificed after six weeks. Notably, the PCNA index of lung cells of the MWCNT-7 group was increased, compared with the DWCNT group. 186 The results indicate that it is preferable to use CNTs with a small number of layers as carriers for antitumor nanometer preparations. In another study, Fenoglio and colleagues incubated MWCNTs of different thicknesses with murine alveolar macrophages (MH-S) and assessed cytotoxicity based on changes in ROS and glutathione. In these experiments, thin MWCNTs appeared significantly more toxic than the thicker counterparts. 187 MWCNTs with four different shapes were injected into mice by the group of Rittinghausen and the effects on mesothelioma examined. With increased curvature of different MWCNT types, the probability of inducing mesothelioma was decreased. In other words, straight needle-shaped MWCNTs induced the greatest toxicity and carcinogenicity. 188 Luisana et al 189 incubated needle-like and tangled MWCNTs with the mouse macrophage cell line, Raw 264.7, and alveolar macrophages, MH-S. The cell viability value of the needle-like MWCNT-treated group was significantly decreased with high nitrite accumulation in the medium, clearly supporting the theory that MWCNT shape is related to cytotoxicity. Sakamoto and coworkers further compared the carcinogenicity of seven MWCNTs showing differences in size and shape. The carcinogenic rates of four needle-shaped MWCNTs were as high as 100% while tangled MWCNTs did not induce mesothelioma. 190 Comprehensive findings from multiple studies thus suggest that different shapes of CNTs exert differing levels of cytotoxicity, with the greatest toxicity induced by needle-shaped CNTs.
CNT Size
Conclusion
With the extensive development and utilization of nanotechnology in the field of oncology, CNTs have been generated that play an irreplaceable role as anticancer drug carriers. However, these nanomolecules have a number of drawbacks in the clinic. During CNTmediated delivery of anticancer drugs to target organs, free CNTs are retained in the body after dissociation of In recent years, the changes and mechanisms of gene expression associated with CNT toxicity have been a considerable focus of research interest. The development of CNTs as anti-tumor nanometer carriers in the future will depend on the consequences of effective treatment. Due to the special nanostructural properties of CNTs, potential toxic effects and improved biocompatibility may be avoided to ensure clinical drug safety. To achieve these positive effects, we need to clarify the mechanisms underlying CNT-induced toxicity to eliminate toxic nanometer formulations. Furthermore, determination of the absorption, distribution, metabolism and excretion properties of CNTs in the body is essential. In summary, comprehensive evaluation of the safety of nanoformulations, optimization of drug payload and reduction of potential toxicity are essential steps to maximize their anti-tumor effects.
